AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...

Tiffany Meng, PharmD, oncology pharmacist, UCSF Health, discusses ways that pharmacists can help guide patients to financial ...

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

Stephanie Seban has devoted the last 14 years of her life to being a 'north star' to other young women facing stage four ...

(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...

Learn more about where breast cancer could metastasize, to prepare you for conversations with your doctor When breast cancer ...

Philecia La'Bounty uses social media to encourage others to get screenings, be open about their experiences and share her own battles — and her followers have shown appreciation. Read more about her ...

Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...

Fox23 meteorologist Laura Mock is sitting in the studio’s weather center following the morning news show and a couple hours ...

PYX-201 has gained FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...